Journal: Microorganisms

Article Title: Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19

doi: 10.3390/microorganisms9112259

Figure Lengend Snippet: Absolute levels at different time points during the study period and antibodies IgA ( A ), IgM ( B ) and IgG ( C ) kinetics in specific patients. Absolute levels of IgA ( A ), IgM ( B ) and IgG ( C ) among the overall study population ( n = 24) at baseline (B), day 3 (D3), day 6 (D6), month 1 (M1), month 3 (M3) and month 6 (M6) after SARS-CoV-2 infection and changes of serum IgA ( A ), IgM ( B ) and IgG ( C ) antibodies in specific patients ( n = 19) at baseline (B), day 3 (D3), day 6 (D6), month 1 (M1), month 3 (M3) and month 6 (M6) after SARS-CoV-2 infection. Patients COV 006, COV 008, COV 009, COV 010, COV 011, COV 013, COV 014 and COV 020 belong to the severe group. ( D ) Comparison of IgG levels between uninfected controls (c) and patients after 6 months of SARS-CoV-2 infection. Mann–Whitney U test. ***, p -value < 0.0001.

Article Snippet: Particularly, serial dilutions of each antibody, standard IgA (ref. 31148—Thermo Fisher Scientific Inc, Waltham, MA, USA), IgM (ref. 31146) or IgG (MP Biomedical—ref.

Techniques: Infection, MANN-WHITNEY